Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005)

Mark Boyd, Preeyaporn Srasuebkul, Mana Khongphattanoyothin, Kiat Ruxrungtham, Elly Hassink, Christopher Duncombe, Sasiwimol Ubolyam, David Burger, Peter Reiss, Michael Stek, Joep Lange, David Cooper, Praphan Phanuphak

    Research output: Contribution to journalArticle

    15 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)223-232
    Number of pages10
    JournalAntiviral Therapy
    Volume11
    Publication statusPublished - 2006

    Cite this

    Boyd, M., Srasuebkul, P., Khongphattanoyothin, M., Ruxrungtham, K., Hassink, E., Duncombe, C., Ubolyam, S., Burger, D., Reiss, P., Stek, M., Lange, J., Cooper, D., & Phanuphak, P. (2006). Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antiviral Therapy, 11, 223-232.